Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 3, 2020updated 21 Oct 2021 11:33am

Russia approves Phase III trial of CanSino’s Covid-19 vaccine

Russia has granted approval for a Phase III clinical trial of China-based CanSino Biologics' Covid-19 vaccine candidate, developed with the Chinese military’s research arm.

Russia has granted approval for a Phase III clinical trial of China-based CanSino Biologics’ Covid-19 vaccine candidate, developed in alliance with the Chinese military’s research arm.

The Phase III trial of the Ad5-nCoV vaccine candidate has been launched in Moscow, following health ministry authorisation. CanSino will work with NPO Petrovax Pharm to conduct the trials in Russia.

A statement from the CanSino said: “The company is currently driving the international multi-centre phase three clinical trial for Ad5-nCoV and plans to conduct the clinical trial for Ad5-nCoV in several countries.”

The Russian approval comes after CanSino and the National Research Council (NRC) of Canada terminated their collaboration on the development of the vaccine.

Trials in Canada were expected to start in July but were cancelled after failing to receive vaccine shipments from China.

CanSino plans to test its vaccine candidate in multiple countries globally. The company expects to enrol a total of approximately 40,000 participants.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Last month, the company announced plans to initiate a Phase III trial of Ad5-nCOV in Saudi Arabia. This trial is set to enrol about 5,000 subjects.

The vaccine candidate is made up of a harmless cold virus known as adenovirus type-5 (Ad5) to deliver genetic material from the coronavirus into the body.

Data from previous trials showed that the candidate was safe and triggered immune responses in most participants. CanSino conducted the first and second phase studies of Ad5-nCoV in China.

The first phase evaluated three different doses of the vaccine in 108 volunteers in China from 16 to 27 March while the second phase tested two doses in 603 subjects from 11 to 16 April.

Results revealed a favourable efficiency profile, with Covid-19 antibodies observed in the plasma of the participants. Few side effects were reported, primarily with low vaccine doses.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy